WO2002046232A3 - Multimeric single-chain antibody with multiple antigen binding - Google Patents

Multimeric single-chain antibody with multiple antigen binding Download PDF

Info

Publication number
WO2002046232A3
WO2002046232A3 PCT/EP2001/014171 EP0114171W WO0246232A3 WO 2002046232 A3 WO2002046232 A3 WO 2002046232A3 EP 0114171 W EP0114171 W EP 0114171W WO 0246232 A3 WO0246232 A3 WO 0246232A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
chain antibody
multiple antigen
multimeric single
multimeric
Prior art date
Application number
PCT/EP2001/014171
Other languages
German (de)
French (fr)
Other versions
WO2002046232A2 (en
Inventor
Roland Kontermann
Original Assignee
Vectron Therapeutics Ag
Roland Kontermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectron Therapeutics Ag, Roland Kontermann filed Critical Vectron Therapeutics Ag
Priority to AU2002229605A priority Critical patent/AU2002229605A1/en
Publication of WO2002046232A2 publication Critical patent/WO2002046232A2/en
Publication of WO2002046232A3 publication Critical patent/WO2002046232A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to multimers of single-chain antibodies with multiple antigen binding, in particular cyclic homodimers, the production and use thereof.
PCT/EP2001/014171 2000-12-04 2001-12-04 Multimeric single-chain antibody with multiple antigen binding WO2002046232A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002229605A AU2002229605A1 (en) 2000-12-04 2001-12-04 Multimeric single-chain antibody with multiple antigen binding

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10060140A DE10060140A1 (en) 2000-12-04 2000-12-04 Multimeric multi-antigen binding single chain antibody
DE10060140.5 2000-12-04

Publications (2)

Publication Number Publication Date
WO2002046232A2 WO2002046232A2 (en) 2002-06-13
WO2002046232A3 true WO2002046232A3 (en) 2002-12-12

Family

ID=7665685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014171 WO2002046232A2 (en) 2000-12-04 2001-12-04 Multimeric single-chain antibody with multiple antigen binding

Country Status (3)

Country Link
AU (1) AU2002229605A1 (en)
DE (1) DE10060140A1 (en)
WO (1) WO2002046232A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2361936T (en) * 2010-02-25 2016-07-15 Affimed Gmbh Antigen-binding molecule and uses thereof
CN110272497B (en) * 2019-02-26 2022-04-08 内蒙古医科大学附属医院 High-affinity anti-cyclic citrullinated peptide tetravalent small-molecule antibody and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816141A1 (en) * 1998-04-09 1999-10-14 Hoechst Marion Roussel De Gmbh New polyspecific binding agents containing variable heavy and light constructs connected via peptide linker, used for treatment, prevention or diagnosis of e.g. cancer
WO1999057150A2 (en) * 1998-05-05 1999-11-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816141A1 (en) * 1998-04-09 1999-10-14 Hoechst Marion Roussel De Gmbh New polyspecific binding agents containing variable heavy and light constructs connected via peptide linker, used for treatment, prevention or diagnosis of e.g. cancer
WO1999057150A2 (en) * 1998-05-05 1999-11-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. KORTT ET AL.: "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.", BIOMOLECULAR ENGINEERING, vol. 18, no. 3, 15 October 2001 (2001-10-15), New York, NY, VSA, pages 95 - 108, XP004305907 *
F. LE GALL ET AL.: "Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding.", FEBS LETTERS, vol. 453, no. 1-2, 18 June 1999 (1999-06-18), Amsterdam, die Niederlande, pages 164 - 168, XP004259822 *
O. DOLEZAL ET AL.: "ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.", PROTEIN ENGINEERING, vol. 13, no. 8, August 2000 (2000-08-01), Oxford, Grossbritannien, pages 565 - 574, XP002210247 *
P. HUDSON ET AL.: "High avidity scFv multimers; diabodies and triabodies.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), Amsterdam, die Niederlande, pages 177 - 189, XP004187644 *

Also Published As

Publication number Publication date
AU2002229605A1 (en) 2002-06-18
DE10060140A1 (en) 2002-06-06
WO2002046232A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
LUC00025I2 (en)
IL178838A (en) Antibodies that bind specifically to human p-psgl-1 and p-selectin, pharmaceutical compositions comprising the antibody and nucleic acids and vectors encoding the same
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2004049794A3 (en) Single chain antibodies produced in a transgenic mouse
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2003074679A3 (en) Antibody optimization
DE69939820D1 (en) INTERNALIZING ERBB2 ANTIBODIES
WO2006085938A3 (en) Il-13 binding agents
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
IL174304A0 (en) Kid3 and kid3 antibodies that bind thereto
MXPA03007319A (en) Modified anti-egfr antibodies with reduced immunogenicity.
EP1599228A4 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
WO2007114861A3 (en) Il-21 receptor antagonists
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2005019270A3 (en) Endotheliase-2 ligands
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2005051999A3 (en) Substance binding human igg fc receptor iib
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
EP1434799A4 (en) Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
WO2002046232A3 (en) Multimeric single-chain antibody with multiple antigen binding
WO2007144619A3 (en) Antibodies selectively binding aggregated prion protein 106-126 and uses thereof
WO2006085092A3 (en) Methods and uses of antibodies in the purification of interferon
WO2006093552A3 (en) Second tc complex from xenorhabdus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP